Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iopofosine I 131 vs R-CD in Previously Treated Waldenstrom Macroglobulinemia
NCT07766421Phase 3Not yet recruiting
- Sponsor
- Cellectar Biosciences
- Start
- Dec 2026
- Primary completion
- Jan 2032
01
Overview
A Phase 3 trial of Iopofosine I-131 in Waldenstrom macroglobulinemia (WM), sponsored by Cellectar Biosciences. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
Iopofosine I-131
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT07766421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07766421.